Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP2B1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP2B1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP2B1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ATP2B1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP2B1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP2B1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP2B1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATP2B1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATP2B1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004343417 | Prostate | BPH | response to peptide hormone | 109/3107 | 414/18723 | 2.73e-07 | 5.91e-06 | 109 |
GO:00713759 | Prostate | BPH | cellular response to peptide hormone stimulus | 82/3107 | 290/18723 | 3.65e-07 | 7.65e-06 | 82 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:00015039 | Prostate | BPH | ossification | 107/3107 | 408/18723 | 4.31e-07 | 8.83e-06 | 107 |
GO:005138416 | Prostate | BPH | response to glucocorticoid | 49/3107 | 148/18723 | 6.20e-07 | 1.21e-05 | 49 |
GO:000926610 | Prostate | BPH | response to temperature stimulus | 56/3107 | 178/18723 | 6.74e-07 | 1.30e-05 | 56 |
GO:003286910 | Prostate | BPH | cellular response to insulin stimulus | 61/3107 | 203/18723 | 1.26e-06 | 2.20e-05 | 61 |
GO:003196016 | Prostate | BPH | response to corticosteroid | 52/3107 | 167/18723 | 2.34e-06 | 3.81e-05 | 52 |
GO:00713858 | Prostate | BPH | cellular response to glucocorticoid stimulus | 24/3107 | 56/18723 | 3.19e-06 | 5.02e-05 | 24 |
GO:003286810 | Prostate | BPH | response to insulin | 73/3107 | 264/18723 | 3.80e-06 | 5.83e-05 | 73 |
GO:00713847 | Prostate | BPH | cellular response to corticosteroid stimulus | 24/3107 | 61/18723 | 1.86e-05 | 2.29e-04 | 24 |
GO:19016554 | Prostate | BPH | cellular response to ketone | 32/3107 | 96/18723 | 4.48e-05 | 4.73e-04 | 32 |
GO:009730517 | Prostate | BPH | response to alcohol | 65/3107 | 253/18723 | 1.42e-04 | 1.27e-03 | 65 |
GO:009025710 | Prostate | BPH | regulation of muscle system process | 64/3107 | 252/18723 | 2.26e-04 | 1.81e-03 | 64 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:00513857 | Prostate | BPH | response to mineralocorticoid | 13/3107 | 36/18723 | 3.71e-03 | 1.87e-02 | 13 |
GO:00514126 | Prostate | BPH | response to corticosterone | 9/3107 | 22/18723 | 5.92e-03 | 2.73e-02 | 9 |
GO:00973062 | Prostate | BPH | cellular response to alcohol | 25/3107 | 93/18723 | 8.12e-03 | 3.53e-02 | 25 |
GO:00075848 | Prostate | BPH | response to nutrient | 41/3107 | 174/18723 | 1.09e-02 | 4.50e-02 | 41 |
GO:006024910 | Prostate | BPH | anatomical structure homeostasis | 68/3107 | 314/18723 | 1.10e-02 | 4.53e-02 | 68 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04961 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049611 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049614 | Colorectum | MSS | Endocrine and other factor-regulated calcium reabsorption | 24/1875 | 53/8465 | 1.49e-04 | 1.24e-03 | 7.61e-04 | 24 |
hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049615 | Colorectum | MSS | Endocrine and other factor-regulated calcium reabsorption | 24/1875 | 53/8465 | 1.49e-04 | 1.24e-03 | 7.61e-04 | 24 |
hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049726 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049616 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
hsa040222 | Colorectum | FAP | cGMP-PKG signaling pathway | 42/1404 | 167/8465 | 2.84e-03 | 1.27e-02 | 7.70e-03 | 42 |
hsa04261 | Colorectum | FAP | Adrenergic signaling in cardiomyocytes | 38/1404 | 154/8465 | 6.16e-03 | 2.34e-02 | 1.42e-02 | 38 |
hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
hsa04970 | Colorectum | FAP | Salivary secretion | 24/1404 | 93/8465 | 1.52e-02 | 4.99e-02 | 3.03e-02 | 24 |
hsa04925 | Colorectum | FAP | Aldosterone synthesis and secretion | 25/1404 | 98/8465 | 1.55e-02 | 4.99e-02 | 3.04e-02 | 25 |
hsa049727 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049617 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
hsa040223 | Colorectum | FAP | cGMP-PKG signaling pathway | 42/1404 | 167/8465 | 2.84e-03 | 1.27e-02 | 7.70e-03 | 42 |
hsa042611 | Colorectum | FAP | Adrenergic signaling in cardiomyocytes | 38/1404 | 154/8465 | 6.16e-03 | 2.34e-02 | 1.42e-02 | 38 |
hsa040241 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP2B1 | SNV | Missense_Mutation | novel | c.2065G>A | p.Glu689Lys | p.E689K | P20020 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ATP2B1 | SNV | Missense_Mutation | | c.1486N>A | p.His496Asn | p.H496N | P20020 | protein_coding | deleterious(0.03) | benign(0.201) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ATP2B1 | SNV | Missense_Mutation | | c.763N>A | p.Asp255Asn | p.D255N | P20020 | protein_coding | tolerated(0.15) | benign(0.403) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
ATP2B1 | SNV | Missense_Mutation | | c.2063C>A | p.Pro688His | p.P688H | P20020 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
ATP2B1 | SNV | Missense_Mutation | novel | c.1790N>A | p.Arg597Gln | p.R597Q | P20020 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2B1 | SNV | Missense_Mutation | | c.703N>A | p.Asp235Asn | p.D235N | P20020 | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2B1 | SNV | Missense_Mutation | | c.3007A>G | p.Ile1003Val | p.I1003V | P20020 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP2B1 | SNV | Missense_Mutation | | c.2563N>C | p.Phe855Leu | p.F855L | P20020 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-C8-A12O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP2B1 | SNV | Missense_Mutation | novel | c.2222G>A | p.Arg741Lys | p.R741K | P20020 | protein_coding | tolerated(0.15) | benign(0.033) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATP2B1 | SNV | Missense_Mutation | novel | c.3278N>C | p.Ile1093Thr | p.I1093T | P20020 | protein_coding | deleterious(0.03) | benign(0.079) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |